Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics


Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung cancer patients.

According to the agreement, Sheba Medical Centre will be responsible for collection of whole blood, peripheral blood mononuclear cells (PBMCs) and serum samples, while Rosetta Genomics will be responsible to identify the miRNAs associated with the response by using its proprietary microarray design and qRT-PCR platform.

Enamine and Pcovery have entered an agreement to develop novel drugs for the treatment of invasive fungal infections.

"The agreement enables the partners to develop a new technology platform for the treatment of fungal infections."

The two partners will jointly develop new composition of matter generation, and the IP produced will belong to Pcovery.

The agreement enables the partners to develop a new technology platform for the treatment of fungal infections.

Wuxi Biologics has signed a memorandum of understanding (MOU) with Prima Biomed Ltd to form a strategic biologics development and manufacturing partnership for the development of IMP321.

According to the agreement, Prima Biomed will be responsible for clinical manufacture of IMP321 in China, Macau, Taiwan and Hong Kong, while Wuxi Biologics will be responsible for the other parts of the world.

The partnership enables the two partners to develop a novel immunotherapy candidate for the treatment of cancer.

Pharming Group plans to raise gross proceeds of approximately $47.7m through the private placement of bonds.

Roth Capital Partners and Stifel Nicolaus Europe are acting as the placements agents for the offering.

The company plans to invest the funds to acquire all commercialisation rights to Ruconest in North America from Valeant Pharma and also increase the sales of Ruconest.

Fate Therapeutics plans to raise $37.5m through the private placement of 2.8 million shares of class A convertible preferred stock.

The company plans to use the proceeds to further develop its product pipeline for cellular immunotherapies and general corporate purposes.